---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019328"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2023-11-27T23:59:59+00:00"
generated_at: "2026-06-07T21:26:58.718316+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coherus sets LOQTORZI price at $8,892.03/vial for NPC treatment

## Summary
- FDA approved LOQTORZI (toripalimab-tpzi) on Oct 27 for first-line and later-line metastatic NPC.
- Coherus announced wholesale acquisition cost of $8,892.03 per single-use vial on Nov 27.
- LOQTORZI is co-administered with cisplatin and gemcitabine in first-line setting.
- This pricing establishes commercial launch basis for the PD-1 inhibitor in NPC.

## SEC filing metadata
- accession: 0001558370-23-019328
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2023-11-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837023019328/0001558370-23-019328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837023019328/chrs-20231127x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019328
- JSON: https://secwatch.observer/filing/0001558370-23-019328.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019328.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.